To include your compound in the COVID-19 Resource Center, submit it here.

Bardoxolone methyl: Phase III started

Reata and Abbott began the double-blind, placebo-controlled, international Phase III BEACON trial to evaluate once-daily 20 mg oral bardoxolone methyl in about

Read the full 223 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE